First-Line Gefitinib Bei Nachweis Aktivierender EGFR-Mutationen

Best Practice Onkologie - Germany
doi 10.1007/s11654-012-5010-x
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

Springer Science and Business Media LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy